📞Call us
+91 80629 16290
Pramodini Medicare Ltd IPO
Status: Upcoming
Overview
IPO date
12 Aug 2026 to 14 Aug 2026
Face value
₹ 10 per share
Price
₹ 110 to ₹118 per share
Issue Size
5,851,200 shares
(aggregating up to ₹ 69.04 Cr)
(aggregating up to ₹ 69.04 Cr)
Allotment Date
17 Aug 2026
Listing at
NSE
Issue type
Book Building - SME
Sector
Healthcare
Unlock Stock of the Month
T&C*
Strengths vs Risks of Pramodini Medicare Ltd
Know the pros & cons
Strengths
- Establishing a Strategic presence across various states of India.
- Strengthening Our Network with Diversified Models.
- Technical Capability with robust IT Infrastructure.
- Dedicated Management Team with Significant Industry Experience.
- Track record of revenue and financial performance.
- Diverse Customer cum Patient Base.
Risks
- A significant portion of our revenue from operations is derived from MOUs with government authorities under Public Private Partnership (PPP) arrangements. Any non-renewal, modification, or termination of such MOUs, or delays or failures in realizing payments from government authorities, may materially and adversely affect our business, financial condition and results of operations.
- Concentrated emphasis on radiology services also exposes us to substantial risks that could adversely impact our operations, financial performance, and long-term growth prospects.
- We derive substantial portion of our revenue from the state of Andhra Pradesh and any loss of business in such regions could have an adverse effect on our business, results of operations and financial condition.
- We are majorly dependent on certain key customers cum patients for a substantial portion of our revenues. Loss of relationship with any of these customers cum patients may have a material adverse effect on our profitability and results of operations.
- We derive a significant portion of our revenue from government authorities (B2G). Any reduction in revenue from them or delays in payments by government authorities, may adversely affect our business, financial condition and results of operations.
- Failure to establish and comply with appropriate quality standards when performing diagnostics services could result in litigation and liability for us and could materially and adversely affect its reputation and results of operations.
- We rely on our information technology systems in providing our diagnostic services and managing our operations, and any disruption to such systems or networks could adversely affect our business operations, reputation and financial performance.
- Any inadequacy in packaging, collection of, or failure or delay in the delivery of, specimens to our diagnostic centres could compromise or destroy the integrity of such specimens, which could adversely affect our business, results of operations and financial condition.
- Our Company is not having any exact comparable Indian peer which have similar business to our Company.
- We are required to furnish bank guarantees as part of our business under Strategic Partnership with PSU Govt of India. Our inability to arrange such guarantees or the invocation of such guarantees may adversely affect our cash flows and financial condition.
- The prices that we can charge for our diagnostic services are dependent on recommended or mandatory fees fixed under the terms of the MOUs entered into with public sector enterprises, state governments and some of private medical establishments.
- We have not yet placed orders in relation to the capital expenditure requirements of the Company towards purchase of certain medical equipments for our existing and proposed diagnostic centres. In the event of any delay in placing the orders, or if the vendors are unable to provide the equipments in a timely manner, or at all, the same may result in time and cost overruns.
- We are subject to extensive regulatory requirements governing our operations, and any failure to comply with such requirements may expose us to penalties and adversely affect our business, operations and financial condition.
- Our utilisation of a portion of the Net Proceeds towards unidentified acquisitions is based on management estimates, which have not been independently appraised by a bank or a financial institution and our inability to identify or complete such acquisitions may adversely affect our growth and competitiveness.
- Certain licenses for the Company's diagnostic equipment are held in the name of the Company and individual personnel in accordance with the prescribed regulatory format and requirements of Atomic Energy Regulatory Board, and any delay in updating the name of employees in such licenses may affect the Company's ability to use such equipment.
- Certain diagnostic centres have been established and are operated under Public Private Partnership contracts awarded by government agencies through a competitive bidding process. There can be no assurance that we will qualify for, or that we will successfully compete and win such tenders.
- We have certain outstanding litigation against us, an adverse outcome of which may adversely affect our business, reputation and results of operations.
- We rely on third parties for certain aspects of our operations, and any deficiency in services provided by them could adversely affect our business and reputation.
- Our Company had negative cash flows in the past years, details of which are given below. Sustained negative cash flow could impact our growth and business.
- Our Company has extended a corporate guarantee in favour of Sri Ram Medicare Private Limited, a promoter group entity, in relation to its borrowings, and any invocation of such guarantee may adversely affect our business, financial condition, cash flows and results of operations; further, such related party arrangements may give rise to conflicts of interest.
- Failure to introduce new tests, services, equipment and technologies could adversely affect our business, results of operations and financial condition.
- We may be unable to retain or recruit trained professionals, which may adversely impact the reputation of our Company and materially and adversely affect our results of operations and cash flows.
- There are certain discrepancies/errors/delay filings noticed in some of our corporate records relating to forms filed with the Registrar of Companies and other provisions of Companies Act, 2013. Any penalty or action taken by any regulatory authorities in future, for non-compliance with provisions of corporate or any other law could impact the financial position of the Company to that extent.
- There are certain discrepancies and non-compliances noticed in some of our financial reporting and/or records relating to filing of returns and deposit of statutory dues with the taxation and other statutory authorities.
- We may become subject to professional malpractice liability claims, which could be costly and, therefore, could negatively affect our business, results of operations and financial condition.
- The diagnostics industry in India is highly competitive and our inability to compete effectively may adversely affect our business, results of operations and financial condition.
- We have certain contingent liabilities that have not been provided for in our financial statements, which if they materialise, may adversely affect our financial condition.
- Our Company has entered into related party transactions in the past and may continue to enter into related party transactions in the future, which may potentially involve conflicts of interest with the equity shareholders
- We depend on third-parties to purchase diagnosis and imaging equipments, and any failure to continue to do so could adversely affect our business, results of operations and financial condition.
- Although we endeavour to ensure compliance with all applicable laws through our internal processes and third-party consultants, there can be no assurance that inadvertent lapses or interpretational differences will not arise in the future. Any such instances may have a material adverse effect on our business, financial performance, and operational continuity.
- We are required to comply with certain restrictive covenants under our financing agreements. Any noncompliance may lead to, amongst others, suspension of further drawdowns, which may adversely affect our business, results of operations, financial condition and cash flows.
- Certain of the Company's agreements may be insufficiently stamped and, accordingly, may not be admissible in evidence or enforceable unless the applicable stamp duty and penalties are paid, which could adversely affect the Company's ability to enforce its rights.
- Employee misconduct or failure of our internal processes or procedures could harm us by impairing our ability to attract and retain patients and subject us to significant legal liability and reputational harm.
- Failure or malfunction of our equipment could adversely affect our ability to conduct our operations.
- Disruption to or failure of transportation services for samples or test kits and other materials could materially and adversely affect our business and financial results.
- We are dependent on a number of key personnel, including our senior management and qualified and experienced laboratory professionals, and the loss of, or our inability to attract or retain such persons could adversely affect our business, results of operations and financial condition.
- The Company has received a notice dated November 25, 2020 in relation to non-payment of tax deducted at source, and any adverse outcome or further action by the tax authorities may expose it to liabilities.
- Business interruption at our diagnostic centres could result in significant losses and reputational damage to our business.
- Our Group Companies namely, Infer Radiological and Imaging Services Private Limited and Vista Pramodini Medicare Private Limited have incurred losses in the past and may incur losses in the future which could have an adverse effect on our business and results of operations.
- Financial difficulties of patients or third-party payers may result in payment delays or require us to write off debts.
- The Company is subject to performance obligations under certain of its contracts, including requirements to furnish performance guarantees and exposure to liquidated damages, and any failure to meet such obligations may result in financial liabilities and impact its operations.
- Our business is capital intensive. If we experience insufficient cash flows from our operations or are unable to borrow to meet our capital requirements, it may materially and adversely affect our business and results of operations.
- Certain of the Company's employee and consultant arrangements may not be fully formalised or may not contain all standard contractual provisions.
- We are subject to data privacy and information security requirements, and any failure to protect patient information or comply with applicable laws may expose us to liabilities and adversely affect our business and reputation.
- Certain details relating to one of our Independent Director Dr. Eshwar Chandra Nandury have not been provided to the Company due to his unwillingness to furnish such information.
- We have not commissioned an industry report for the disclosures made in the section titled `Industry Overview' and made disclosures on the basis of the data available on the internet and such data has not been independently verified by us.
- Our operations are conducted from leased premises where certain approvals are dependent on third parties, and any deficiencies in such approvals may affect our ability to operate from such locations.
- We are significantly dependent on the patients of the healthcare facilities within which we deploy and operate our diagnostic centres. A failure to obtain and retain new patients by such facilities or the loss of existing patients could impact our ability to successfully grow our business.
- Our business and operations would suffer in the event of computer system failures, cyber-attacks or deficiencies in our cyber-security.
- Our insurance coverage may not be sufficient or may not adequately protect us against all material hazards, which may adversely affect our business, results of operations and financial condition.
- Our Company logo "Pramodini Medicare Limited" is not registered with Registrar of Trademark; any infringement of our brand name or failure to get it registered may adversely affect our business.
- We may, in the future, engage in acquisitions and joint ventures. We may not be able to complete such transactions, and such transactions, if executed, pose significant risks.
- We are subject to risks arising from interest rate, which could adversely affect our business, financial condition and results of operations.
- Significant differences exist between Indian GAAP and other accounting principles, such as US GAAP and IFRS, which may be material to investors assessments of Our Company's financial condition. Our failure to successfully adopt IFRS may have an adverse effect on the price of our Equity Shares. The proposed adoption of IFRS could result in our financial condition and results of operations appearing materially different than under Indian GAAP.
- In addition to normal remuneration, other benefits and reimbursement of expenses, some of our directors (including our Promoters) are interested in our Company to the extent of their shareholding, rent and dividend entitlement in our Company.
- Any variation in the utilisation of the Net Proceeds would be subject to certain compliance requirements, including prior shareholders' approval.
- After the completion of the Offer, our Promoters along with the Promoter Group will continue to control our Company.
- Our operations are human capital intensive and our operations may be materially adversely affected by strikes, work stoppages or increased salary demands by our employees.
- We have issued Equity Shares during the preceding twelve months at a price which may be below the Offer Price.
- If we fail to maintain an effective system of internal controls, we may not be able to successfully manage, or accurately report, our financial risks. Despite our internal control systems, we may be exposed to operational risks, including fraud, petty theft and embezzlement, which may adversely affect our reputation, business, financial condition, results of operations and cash flows.
- We are dependent on government policies and budget allocations for diagnostic centres that we intend to establish in future and our overall growth.
- Our ability to pay dividends in the future will depend on our earnings, financial condition, working capital requirements, capital expenditures and restrictive covenants of our financing arrangements.
- We will not receive any proceeds from the Offer for Sale. The Promoter Selling Shareholders will receive the net proceeds from the Offer for Sale.
- Our Group Companies namely, Infer Radiological and Imaging Services Private Limited and Vista Pramodini Medicare Private Limited have been formed to engage in line of business that is synergistic to our business and consequently the interest of these Companies may be in conflict with the interest of our Company in the future.
- Our directors are associated with other companies which are in businesses similar to ours.
- Some of our Directors and Promoters have interests ours Associate Companies engaged in businesses similar to us.
- The determination of the Price Band is based on various factors and assumptions and the Offer Price of the Equity Shares may not be indicative of the market price of the Equity Shares upon listing on the Stock Exchange.
- We have presented certain supplemental information of our performance and liquidity which is not prepared under or required under AS.
- Pursuant to listing of the Equity Shares, we may be subject to pre-emptive surveillance measures like Additional Surveillance Measure (ASM) and Graded Surveillance Measures (GSM) by the Stock Exchange in order to enhance market integrity and safeguard the interest of investors.
- Some of our Directors do not have experience of being a director of a public listed company.
Pramodini Medicare Ltd Peer Comparison
Understand the company’s industry standing
Pramodini Medicare Limited
Invicta Diagnostic Limited
Krsnaa Diagnostics Limited
Face Value
10
10
5
Standalone / Consolidated
Consolidated
Standalone
Standalone
Total Income Rs. Cr.
---
---
---
EPS-Basis
6.92
5.57
24.04
EPS-Diluted
6.92
5.57
24.04
NAV Per Share
19.52
18.81
273.39
P/E-Basic EPS
---
14.52
25.15
P/E-Diluted EPS
---
---
---
RONW(%)
30.81
29.63
8.79
Latest NAV Period
---
---
---
Latest NAV
---
---
---
How to check the allotment status of Pramodini Medicare Ltd IPO?
Follow the steps
Open link to the registrar using this URL (https://evault.kfintech.com/ipostatus/).
Select company from dropdown menu.
Enter details- PAN, Application number or DP client ID
Get your allotment status
Open link to the registrar using this URL (https://evault.kfintech.com/ipostatus/).
IPO reads
Stay updated with the latest IPO developments
February 27, 2025 | 5 min read
₹50.11 Cr Balaji Phosphates IPO Opens Feb 28. Issue Details and SWOT AnalysisRead More
February 25, 2025 | 5 min read
Tata Capital Board Approves ₹15,000 Cr Plus Mega IPO; Tata Investment Shares Soar 8%Read More
February 18, 2025 | 5 min read
Busy Week Ahead: 2 SME IPOs and 9 Market Listings – Get the Complete Details HereRead More
October 25, 2024 | 5 min read
Waaree Energies IPO: GMP Soars 106% Amid 76.34x Subscription – Check Your Allotment Status!Read More
October 22, 2024 | 5 min read
Upcoming IPOs: 9 Public Issues Set to Raise ₹10,984.8 Cr – Key Insights Inside!Read More
October 17, 2024 | 5 min read
Hyundai IPO Hits a Speed Bump With 42% Subscription On Day 2 : 4 Reasons WhyRead More
September 6, 2024 | 5 min read
Bajaj Housing Finance IPO: All You Need to KnowRead MoreOctober 17, 2024 | 5 min read
Hyundai IPO Hits a Speed Bump With 42% Subscription On Day 2 : 4 Reasons WhyRead More
August 26, 2024 | 5 min read
Premier Energies IPO: Key Details Ahead of the ₹2,830.40 Cr Issue LaunchRead MoreMore on IPOs
Navigate your way to other IPO resources
Latest videos on IPOs
IPO highlights & details!
FAQs on IPO
Get answers to all your questions here!
The IPO opens on 12 Aug 2026 & closes on 14 Aug 2026.
Pramodini Medicare Limited was originally incorporated on September 12, 2000 as 'Pramodini Medicare Private Limited' with the Registrar of Companies, Andhra Pradesh. Thereafter, the status of the Company changed to public limited Company and the name was changed to 'Pramodini Medicare Limited' vide fresh certificate of incorporation dated November 12, 2025.
Company was originally incorporated in the year 2000 with the objective to provide diagnostic services. The Company provide a range of technology-enabled diagnostic services such as radiology, clinical laboratory and nuclear medicine service to public hospitals, private hospitals, certain PSU (Public Sector Undertaking) of Government of India and medical colleges across tier I, tier II and tier III cities throughout India.
Diagnostic services include a comprehensive range of offerings: (i) 'Radiology' which covers Magnetic Resonance Imaging (MRI), Computed Tomography (CT scan), X- ray, Ultrasound with colour doppler, Mammography, DEXA Scan and Intervention Radiology, (ii) 'Clinical Laboratory' which includes Haematology, Micro-Biology, Immunology, Pathology & Bio-Chemistry and (iii) 'Nuclear Medicine' which includes PET-CT (Positron Emission Tomography-Computed Tomography), SPECT (Single Photon Emission Computed Tomography) and Nuclear therapy.
The Company provide teleradiology services through its registered office situated at Vijayawada which functions on a 24x7 basis throughout the year. It provide healthcare services for core testing, patients diagnosis, disease prevention and monitoring of various health conditions. The services includes both routine and specialized tests, which are used for prediction, early detection, diagnostic screening, confirmation and/or monitoring of diseases.
Apart from these, the business operates across four key models mainly the Public Private Partnership (with government hospitals and government teaching hospitals), Private Private Partnership (with private sector hospitals), Strategic Partnership with PSUs (Public Sector Undertakings) Government of India and Private Centres (standalone centre).
The company has filed a Draft Prospectus with SEBI for the IPO by issuing the aggregate of 58,51,200 equity shares of Rs 10 each, which consist a fresh issue of 53,50,000 equity shares and the offer for sale of 5,00,400 equity shares.
Pramodini Medicare Ltd IPO will close on 14 Aug 2026.
- Establishing a Strategic presence across various states of India.
- Strengthening Our Network with Diversified Models.
- Technical Capability with robust IT Infrastructure.
- Dedicated Management Team with Significant Industry Experience.
- Track record of revenue and financial performance.
- Diverse Customer cum Patient Base.
| S.No | Promoters Name | Pre Issue Shares | Pre Issue Percentage | Post Issue Shares | Post Issue Percentage |
|---|---|---|---|---|---|
| 1 | Chalasani Kuldeep Kumar | 8087586 | 48.44 | 7873186 | 35.71 |
| 2 | Chalasani Kavitha | 1634737 | 9.79 | 1491737 | 6.77 |
| 3 | Chalasani Durga Aashritha | --- | --- | --- | --- |
| 4 | Sri Ram Medicare Private Limit | 4587154 | 27.48 | 4444154 | 20.16 |
| 5 | Chalasani Lalithakumari | --- | --- | --- | --- |
- A significant portion of our revenue from operations is derived from MOUs with government authorities under Public Private Partnership (PPP) arrangements. Any non-renewal, modification, or termination of such MOUs, or delays or failures in realizing payments from government authorities, may materially and adversely affect our business, financial condition and results of operations.
- Concentrated emphasis on radiology services also exposes us to substantial risks that could adversely impact our operations, financial performance, and long-term growth prospects.
- We derive substantial portion of our revenue from the state of Andhra Pradesh and any loss of business in such regions could have an adverse effect on our business, results of operations and financial condition.
- We are majorly dependent on certain key customers cum patients for a substantial portion of our revenues. Loss of relationship with any of these customers cum patients may have a material adverse effect on our profitability and results of operations.
- We derive a significant portion of our revenue from government authorities (B2G). Any reduction in revenue from them or delays in payments by government authorities, may adversely affect our business, financial condition and results of operations.
- Failure to establish and comply with appropriate quality standards when performing diagnostics services could result in litigation and liability for us and could materially and adversely affect its reputation and results of operations.
- We rely on our information technology systems in providing our diagnostic services and managing our operations, and any disruption to such systems or networks could adversely affect our business operations, reputation and financial performance.
- Any inadequacy in packaging, collection of, or failure or delay in the delivery of, specimens to our diagnostic centres could compromise or destroy the integrity of such specimens, which could adversely affect our business, results of operations and financial condition.
- Our Company is not having any exact comparable Indian peer which have similar business to our Company.
- We are required to furnish bank guarantees as part of our business under Strategic Partnership with PSU Govt of India. Our inability to arrange such guarantees or the invocation of such guarantees may adversely affect our cash flows and financial condition.
- The prices that we can charge for our diagnostic services are dependent on recommended or mandatory fees fixed under the terms of the MOUs entered into with public sector enterprises, state governments and some of private medical establishments.
- We have not yet placed orders in relation to the capital expenditure requirements of the Company towards purchase of certain medical equipments for our existing and proposed diagnostic centres. In the event of any delay in placing the orders, or if the vendors are unable to provide the equipments in a timely manner, or at all, the same may result in time and cost overruns.
- We are subject to extensive regulatory requirements governing our operations, and any failure to comply with such requirements may expose us to penalties and adversely affect our business, operations and financial condition.
- Our utilisation of a portion of the Net Proceeds towards unidentified acquisitions is based on management estimates, which have not been independently appraised by a bank or a financial institution and our inability to identify or complete such acquisitions may adversely affect our growth and competitiveness.
- Certain licenses for the Company's diagnostic equipment are held in the name of the Company and individual personnel in accordance with the prescribed regulatory format and requirements of Atomic Energy Regulatory Board, and any delay in updating the name of employees in such licenses may affect the Company's ability to use such equipment.
- Certain diagnostic centres have been established and are operated under Public Private Partnership contracts awarded by government agencies through a competitive bidding process. There can be no assurance that we will qualify for, or that we will successfully compete and win such tenders.
- We have certain outstanding litigation against us, an adverse outcome of which may adversely affect our business, reputation and results of operations.
- We rely on third parties for certain aspects of our operations, and any deficiency in services provided by them could adversely affect our business and reputation.
- Our Company had negative cash flows in the past years, details of which are given below. Sustained negative cash flow could impact our growth and business.
- Our Company has extended a corporate guarantee in favour of Sri Ram Medicare Private Limited, a promoter group entity, in relation to its borrowings, and any invocation of such guarantee may adversely affect our business, financial condition, cash flows and results of operations; further, such related party arrangements may give rise to conflicts of interest.
- Failure to introduce new tests, services, equipment and technologies could adversely affect our business, results of operations and financial condition.
- We may be unable to retain or recruit trained professionals, which may adversely impact the reputation of our Company and materially and adversely affect our results of operations and cash flows.
- There are certain discrepancies/errors/delay filings noticed in some of our corporate records relating to forms filed with the Registrar of Companies and other provisions of Companies Act, 2013. Any penalty or action taken by any regulatory authorities in future, for non-compliance with provisions of corporate or any other law could impact the financial position of the Company to that extent.
- There are certain discrepancies and non-compliances noticed in some of our financial reporting and/or records relating to filing of returns and deposit of statutory dues with the taxation and other statutory authorities.
- We may become subject to professional malpractice liability claims, which could be costly and, therefore, could negatively affect our business, results of operations and financial condition.
- The diagnostics industry in India is highly competitive and our inability to compete effectively may adversely affect our business, results of operations and financial condition.
- We have certain contingent liabilities that have not been provided for in our financial statements, which if they materialise, may adversely affect our financial condition.
- Our Company has entered into related party transactions in the past and may continue to enter into related party transactions in the future, which may potentially involve conflicts of interest with the equity shareholders
- We depend on third-parties to purchase diagnosis and imaging equipments, and any failure to continue to do so could adversely affect our business, results of operations and financial condition.
- Although we endeavour to ensure compliance with all applicable laws through our internal processes and third-party consultants, there can be no assurance that inadvertent lapses or interpretational differences will not arise in the future. Any such instances may have a material adverse effect on our business, financial performance, and operational continuity.
- We are required to comply with certain restrictive covenants under our financing agreements. Any noncompliance may lead to, amongst others, suspension of further drawdowns, which may adversely affect our business, results of operations, financial condition and cash flows.
- Certain of the Company's agreements may be insufficiently stamped and, accordingly, may not be admissible in evidence or enforceable unless the applicable stamp duty and penalties are paid, which could adversely affect the Company's ability to enforce its rights.
- Employee misconduct or failure of our internal processes or procedures could harm us by impairing our ability to attract and retain patients and subject us to significant legal liability and reputational harm.
- Failure or malfunction of our equipment could adversely affect our ability to conduct our operations.
- Disruption to or failure of transportation services for samples or test kits and other materials could materially and adversely affect our business and financial results.
- We are dependent on a number of key personnel, including our senior management and qualified and experienced laboratory professionals, and the loss of, or our inability to attract or retain such persons could adversely affect our business, results of operations and financial condition.
- The Company has received a notice dated November 25, 2020 in relation to non-payment of tax deducted at source, and any adverse outcome or further action by the tax authorities may expose it to liabilities.
- Business interruption at our diagnostic centres could result in significant losses and reputational damage to our business.
- Our Group Companies namely, Infer Radiological and Imaging Services Private Limited and Vista Pramodini Medicare Private Limited have incurred losses in the past and may incur losses in the future which could have an adverse effect on our business and results of operations.
- Financial difficulties of patients or third-party payers may result in payment delays or require us to write off debts.
- The Company is subject to performance obligations under certain of its contracts, including requirements to furnish performance guarantees and exposure to liquidated damages, and any failure to meet such obligations may result in financial liabilities and impact its operations.
- Our business is capital intensive. If we experience insufficient cash flows from our operations or are unable to borrow to meet our capital requirements, it may materially and adversely affect our business and results of operations.
- Certain of the Company's employee and consultant arrangements may not be fully formalised or may not contain all standard contractual provisions.
- We are subject to data privacy and information security requirements, and any failure to protect patient information or comply with applicable laws may expose us to liabilities and adversely affect our business and reputation.
- Certain details relating to one of our Independent Director Dr. Eshwar Chandra Nandury have not been provided to the Company due to his unwillingness to furnish such information.
- We have not commissioned an industry report for the disclosures made in the section titled `Industry Overview' and made disclosures on the basis of the data available on the internet and such data has not been independently verified by us.
- Our operations are conducted from leased premises where certain approvals are dependent on third parties, and any deficiencies in such approvals may affect our ability to operate from such locations.
- We are significantly dependent on the patients of the healthcare facilities within which we deploy and operate our diagnostic centres. A failure to obtain and retain new patients by such facilities or the loss of existing patients could impact our ability to successfully grow our business.
- Our business and operations would suffer in the event of computer system failures, cyber-attacks or deficiencies in our cyber-security.
- Our insurance coverage may not be sufficient or may not adequately protect us against all material hazards, which may adversely affect our business, results of operations and financial condition.
- Our Company logo "Pramodini Medicare Limited" is not registered with Registrar of Trademark; any infringement of our brand name or failure to get it registered may adversely affect our business.
- We may, in the future, engage in acquisitions and joint ventures. We may not be able to complete such transactions, and such transactions, if executed, pose significant risks.
- We are subject to risks arising from interest rate, which could adversely affect our business, financial condition and results of operations.
- Significant differences exist between Indian GAAP and other accounting principles, such as US GAAP and IFRS, which may be material to investors assessments of Our Company's financial condition. Our failure to successfully adopt IFRS may have an adverse effect on the price of our Equity Shares. The proposed adoption of IFRS could result in our financial condition and results of operations appearing materially different than under Indian GAAP.
- In addition to normal remuneration, other benefits and reimbursement of expenses, some of our directors (including our Promoters) are interested in our Company to the extent of their shareholding, rent and dividend entitlement in our Company.
- Any variation in the utilisation of the Net Proceeds would be subject to certain compliance requirements, including prior shareholders' approval.
- After the completion of the Offer, our Promoters along with the Promoter Group will continue to control our Company.
- Our operations are human capital intensive and our operations may be materially adversely affected by strikes, work stoppages or increased salary demands by our employees.
- We have issued Equity Shares during the preceding twelve months at a price which may be below the Offer Price.
- If we fail to maintain an effective system of internal controls, we may not be able to successfully manage, or accurately report, our financial risks. Despite our internal control systems, we may be exposed to operational risks, including fraud, petty theft and embezzlement, which may adversely affect our reputation, business, financial condition, results of operations and cash flows.
- We are dependent on government policies and budget allocations for diagnostic centres that we intend to establish in future and our overall growth.
- Our ability to pay dividends in the future will depend on our earnings, financial condition, working capital requirements, capital expenditures and restrictive covenants of our financing arrangements.
- We will not receive any proceeds from the Offer for Sale. The Promoter Selling Shareholders will receive the net proceeds from the Offer for Sale.
- Our Group Companies namely, Infer Radiological and Imaging Services Private Limited and Vista Pramodini Medicare Private Limited have been formed to engage in line of business that is synergistic to our business and consequently the interest of these Companies may be in conflict with the interest of our Company in the future.
- Our directors are associated with other companies which are in businesses similar to ours.
- Some of our Directors and Promoters have interests ours Associate Companies engaged in businesses similar to us.
- The determination of the Price Band is based on various factors and assumptions and the Offer Price of the Equity Shares may not be indicative of the market price of the Equity Shares upon listing on the Stock Exchange.
- We have presented certain supplemental information of our performance and liquidity which is not prepared under or required under AS.
- Pursuant to listing of the Equity Shares, we may be subject to pre-emptive surveillance measures like Additional Surveillance Measure (ASM) and Graded Surveillance Measures (GSM) by the Stock Exchange in order to enhance market integrity and safeguard the interest of investors.
- Some of our Directors do not have experience of being a director of a public listed company.
The Issue type of Pramodini Medicare Ltd is Book Building - SME.
The minimum application for shares of Pramodini Medicare Ltd is 2400.
The total shares issue of Pramodini Medicare Ltd is 5851200.
Initial public offer of upto 58,51,200* equity shares of face value of Rs. 10/- each (the "Equity Shares") of Pramodini Medicare Limited ("The Company" or "Pramodini" or "The Offeror") at an offer price of Rs. 110-118 per equity share for cash, aggregating up to Rs. 64.36-69.04 Crores comprising of fresh issue of up to 53,50,800 equity shares aggregating to Rs. 58.86-63.14 Crores ("Fresh Issue") and an offer for sale of up to 5,00,400 equity shares by Chalasani Kuldeep Kumar, Chalasani Kavitha and Sri Ram Medicare Private Limited ("Promoter Selling Shareholders") aggregating to Rs. 5.50-5.90 Crores ("Offer For Sale") ("Public Offer"). The offer includes a reservation of up to 3,36,000 equity shares of face value of Rs. 10/- each, at an offer price of Rs. 110-118 per equity share for cash, aggregating Rs. 3.7-3.96 Crores will be reserved for subscription by the market maker to the offer (the "Market Maker Reservation Portion"). The public offer less market maker reservation portion i.e. Net offer of up to 55,15,200 equity shares of face value of Rs.10/-each, at an offer price of Rs. 110-118 per equity share for cash, aggregating upto Rs. 60.67-65.08 Crores is herein after referred to as the "Net Offer". The public offer and net offer will constitute 26.54% and 25.02% respectively of the post- offer paid-up equity share capital of the company.
Price Band: Rs. 110/- to Rs. 118/- per equity share of face value of Rs. 10/- each.
The floor price is 11.00 times the face value of the equity shares and cap price is 11.80 times of the face value of the equity shares.
Bids can be made for a minimum of 1,200 equity shares and in multiples of 1,200 equity shares thereafter.